PSN010 is an oral glucokinase activator (GKA), being developed for the treatment of type 2 diabetes. By activating the enzyme glucokinase, PSN010 is anticipated to lower blood glucose levels by increasing uptake of glucose in the liver and increasing insulin secretion from the pancreas. PSN010 was discovered and developed in-house through OSI's diabetes and obesity research efforts, the project arising from a research collaboration with the Vanderbilt University Diabetes Center and Tanabe Seiyaku Co. Ltd. PSN010 is currently in Phase I clinical trials. In January, 2007, OSI entered into a licensing agreement granting Eli Lilly exclusive rights to its GKA program, which includes PSN010.